Lipid Research Clinics Coronary Primary Prevention Trial (CPPT)
Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Oct 27, 1999
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
Numerous prospective epidemiologic studies have demonstrated that hypercholesterolemia is a major risk factor for atherosclerotic coronary heart disease. Research on animals indicating that the reduction of serum cholesterol prevented or reversed atherosclerosis had not been shown convincingly in humans. The Coronary Primary Prevention Trial tested the hypothesis that lowering the serum cholesterol in patients who had no existing evidence of coronary heart disease would reduce the subsequent rate of coronary heart disease in those persons.
Coronary heart disease is the leading...
Gender
MALE
Eligibility criteria
- • Men, ages 35-59. Type II hyperlipoproteinemia. Free from coronary heart disease.
About National Heart, Lung, And Blood Institute (Nhlbi)
The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Francois Abboud
University of Iowa
Elizabeth Barrett-Connor
University of California, San Diego
Reagan Bradford
Oklahoma Medical Research Foundation
Marilyn Buzzard
University of Minnesota
Gerald Cooper
Centers for Disease Control and Prevention
John Farquhar
Stanford University
Ivan Frantz
University of Minnesota
Anne Goldberg
Washington University School of Medicine
Frank Ibbott
Bio-Science Laboratories
William, Insull
Baylor College of Medicine
Robert Knoop
University of Washington
Peter Kwiterovich
Johns Hopkins University
John LaRosa
George Washington University
J. Little
University of Toronto
L. Sheffield
University of Alabama at Birmingham
Dennis Sprecher
University of Cincinnati
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials